

Please type a plus sign (+) inside this box

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

O I P E
(use as many sheets as necessary)

Sheet 2 of 3

OCT 5 2001

U.S. PATENT & TRADEMARK OFFICE

Complete if Known

Application Number	09/622,613
Filing Date	August 17, 2000
First Named Inventor	Rybak, Susanna M
Group Art Unit	
Examiner Name	Not Yet assigned
Attorney Docket Number	015280-343100US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mt	AF	Ardelt, <i>et al.</i> "Amino Acid Sequence of an Anti-tumor Protein from Rana Pipiens Oocytes and Early Embryosis/Homology to Pancreatic Ribonuclease" <i>J. of Biological Chemistry</i> , (January 1991), Vol. 266(1), pp. 245-251.	✓
	AG	Boix, <i>et al.</i> "Role of the N Terminus in Rnase A Homologues: Differences in Catalytic Activity, Ribonuclease Inhibitor Interaction and Cytotoxicity" <i>J. of Molecular Biology</i> (January 1996), Vol. 257, pp. 992-1007.	
	AH	Inokuchi, <i>et al.</i> "Primary Structure of Base Non-specific and Acid Ribonuclease from Bullfrog (<i>Rana catesbeiana</i>)" <i>Biol. Pharm. Bull</i> (1997) Vol. 20(5), pp. 471-478.	
	AI	Kobe, <i>et al.</i> "A Structural Basis of the Interactions Between Leucine-rich Repeats and Protein Ligands" <i>Nature</i> , (March 1995), Vol. 374, pp. 183-186	
	AJ	Leung, <i>et al.</i> "Recombinant Expression of Ribonuclease of Rana pipien Origin" March 1999 Vol. 40, pp. 353-54	
	AK	Liao, <i>et al.</i> "Large-Scale Preparation of a Ribonuclease from <i>Rana catesbeiana</i> (Bullfrog) Oocytes and Characterization of its Specific Cytotoxic Activity Against Tumor Cells" <i>Protein Expression and Purification</i> (1996) Vol. 7, pp. 194-202.	
	AL	Mansfield, <i>et al.</i> "Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-bearing Cells and Tumors" <i>Blood</i> (September 1997) Vol. 90(5), pp. 2020-2026.	
	AM	Mansfield, <i>et al.</i> "Recombinant RFB4 Single-chain Immunotoxin that is Cytotoxic Towards CD22-positive Cells" <i>Biochem. Soc. Trans.</i> (1997) Vol. 25, pp. 709-714.	
	AN	Mosimann, <i>et al.</i> "Refined 1.7 AA X-ray Crystallographic Structure P-30 Protein, Amphibian Ribonuclease with Anti-tumor Activity" <i>J. of Molecular Biology</i> , January 1994, Vol. 236 (4), pp. 1141-1153.	✓
	AO	Newton, <i>et al.</i> "Anti-tumor Ribonuclease, combined with or Conjugated to Monoclonal Antibody MRK16, Overcomes Multidrug Resistance to Vincristine <i>In Vitro</i> and <i>In Vivo</i> " <i>Int'l. Oncology</i> (1996) Vol. 8, pp. 1095-1104.	
	AP	Newton, <i>et al.</i> "Angiogenin Single-chain Immunofusions: Influence of Peptide Linkers and Spacers Between Fusion Protein Domains" <i>Biochemistry</i> (1996) Vol. 35, pp. 545-553.	

Examiner
Signature

Misook Z

Date
Considered

10-21-02

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1274936 v1

Please type a plus sign (+) inside this box

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

OCT 05 2001

Compleat if Known

Application Number	09/622,613
Filing Date	August 17, 2000
First Named Inventor	Rybak, Susanna M
Group Art Unit	
Examiner Name	Not Yet assigned
Attorney Docket Number	015280-343100US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MY	AQ	Newton, <i>et al.</i> "Expression and Characterization of a Cytotoxic Human-frog Chimeric Ribonuclease: Potential for Cancer Therapy" <i>Protein Engineering</i> (1997) Vol. 10(4), pp. 463-470.	
J	AR	Newton, <i>et al.</i> "Single Amino-acid Substitutions at the N-terminus of a Recombinant Cytotoxic Ribonuclease Markedly Influence Biochemical and Biological Properties" <i>Biochemistry</i> , April 1998, Vol. 37 (15), pp. 5173-5183.	
J	AS	Ryback, <i>et al.</i> "Cytotoxic Onconase and Ribonuclease a Chimeras: Comparison and <i>in Vitro</i> Characterization" <i>Drug Delivery</i> (1993) Vol. 1, pp. 3-10.	

Examiner
Signature

Misook Z

Date
Considered

10-21-02

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1274936 v1